Patheon IncTSX: PTI

Patheon Inc. Announces Its Performance Guarantee

· Issued by Patheon Inc via CNW

RESEARCH TRIANGLE PARK, NC, June 9 /CNW/ - Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today its launch of a new performance guarantee initiative designed to enhance its service to customers. The Patheon Performance Guarantee will be added as a new feature in commercial manufacturing contracts for customers with critical supply requirements.

This Patheon Performance Guarantee builds on Patheon's improving delivery performance and its legacy of quality. The company now regularly exceeds 95% on time, in full delivery and recently delivered 97.5% of customer orders on time across the entire network. Patheon will guarantee delivery performance while building on its reputation for exceptional quality and reliable regulatory compliance. Patheon also reported over 94% right first time batch production performance in April, its highest ever.

Wes Wheeler, President and Chief Executive Officer of Patheon Inc. stated, "Our customers regularly tell us that service and quality are their most important criteria when evaluating contract manufacturers. We have spent the past 18 months focused on measuring all aspects of our business with particular focus on delivery, efficiency and quality. We are now ready to stand by our performance with delivery guarantees."

ABOUT PATHEON INC.

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through the commercial manufacturing of a wide array of dosage forms including parenteral, solid, semi-solid and liquids. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon's ability to integrate development and manufacturing services ensures that our customers' projects are delivered on time and meet the high standards of quality that Patheon is known for. Patheon's integrated development and manufacturing network of 10 facilities and 7 development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases